| Market Capitalization (Millions $) |
34,594 |
| Shares
Outstanding (Millions) |
394 |
| Employees |
11,100 |
| Revenues (TTM) (Millions $) |
4,817 |
| Net Income (TTM) (Millions $) |
930 |
| Cash Flow (TTM) (Millions $) |
212 |
| Capital Exp. (TTM) (Millions $) |
353 |
Business Description
Company Profile: Dexcom Inc.
Overview:
Dexcom Inc. is a leading medical device company focused on the development and manufacturing of continuous glucose monitoring (CGM) systems tailored for individuals with diabetes. Established in 1999 by Scott Krasner and John Wilson, Dexcom has become a prominent name in diabetes care, offering innovative solutions that enhance the quality of life for people managing the condition.
Product Offerings:
Dexcom’s CGM systems consist of a sensor that is inserted beneath the skin to measure glucose levels in the interstitial fluid. These devices are accompanied by transmitters that wirelessly relay real-time glucose data to a receiver or compatible mobile applications, allowing users to monitor their glucose levels continuously. This monitoring capability empowers users to track glucose trends, improving their ability to make informed decisions regarding insulin dosage, dietary choices, and exercise routines.
Key Products:
1. Dexcom G6: The flagship CGM system featuring a smaller sensor, extended wear time, and a no-calibration design. The G6 provides seamless integration with mobile apps, granting users access to real-time glucose readings via their smartphones.
2. Dexcom G5: An earlier version that paved the way for advancements in CGM technology.
3. Dexcom G4 Platinum: A well-established model that has been widely utilized by diabetes patients.
Clinical Accuracy and Approval:
Dexcoms CGM systems are recognized for their high accuracy, achieving a mean absolute difference (MAD) of less than 10% when compared to laboratory reference values. The company’s commitment to safety and efficacy is further highlighted by its receipt of various regulatory approvals, including the FDA approval for the Dexcom G6 system in 2018.
Research and Development:
Dexcom prioritizes research and development, continually investing in the exploration of new technologies and features. Collaborations with prominent diabetes advocacy organizations, healthcare professionals, and academic institutions enhance their ability to innovate and improve diabetes management solutions.
Global Presence:
With operations in the United States, Europe, Asia, and Australia, Dexcom has established a robust global footprint. The company is dedicated to building a supportive community around diabetes management, including a dedicated customer support team and an active online community.
Vision:
Dexcoms vision is to empower individuals with diabetes to lead fulfilling lives by streamlining and improving the management of their condition through advanced technology. The company is committed to making diabetes care more accurate, accessible, and convenient, ultimately enhancing the independence and well-being of its users.
Company Address: 6340 Sequence Drive San Diego 92121 CA
Company Phone Number: 200-0200 Stock Exchange / Ticker: NASDAQ DXCM
|
1.63% 
69.86 %